> AstraZeneca ($AZN) signed a licensing agreement with Starpharma enabling the development and commercialization of targets using the Australian company's drug delivery technology. AstraZeneca will pay Starpharma $2 million up front, and potentially more than $100 million in milestone payments based on product development, launch and sales levels. More
> Aytu BioScience announced that it has completed its private placement convertible note financing, raising $5.175 million in support of its orally disintegrating tablet that's formulated to treat premature ejaculation. More